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Word Count: 3137 
Objectives: To assess 5-year progression of erosions and Joint Space Narrowing 
(JSN), and their associations with RF status in two large, multi-centre early-RA 
cohorts spanning 25-years. 
Methods: Radiographic joint damage was recorded using the Sharp/van der Heijde 
(SvdH) method in the Early RA Study (ERAS) 1986-2001, and the Early RA Network 
(ERAN) 2002-2013. Mixed-effects negative-binomial regression estimated changes in 
radiographic damage over 5-years, including erosions and JSN separately. 
Rheumatoid Factor (RF), along with age, sex and baseline markers of disease activity 
were controlled for. 
Results: 1,216 patients from ERAS and 446 from ERAN had radiographic data. 
Compared to ERAS, ERAN patients had a lower mean total SvdH score at baseline 
(ERAN=6.2 vs. ERAS=10.5, p<0.001), and mean annual rate of change (ERAN=2.5 vs. 
ERAS=6.9 per year, p<0.001). 74% of ERAS and 27% of ERAN patients progressed ≥5 
units. Lower scores at baseline in ERAN were largely driven by reductions in JSN 
(ERAS=3.9 vs. ERAN=1.2, p<0.001), along with erosions (ERAS=1.9 vs. ERAN=0.8, 
p<0.001). RF was associated with greater progression in each cohort, but the 
absolute difference in mean annual rate of change for RF positive patients was 
substantially higher for ERAS (RF+= 8.6 vs. RF-= 5.1, p<0.001), relative to ERAN (RF+= 
2.0 vs. RF-= 1.9, p=0.855). 
Conclusion: Radiographic progression has significantly reduced between the two 
cohorts, associated with lower baseline damage and other factors, including changes 
in early DMARD use. The impact of RF status as a prognostic marker of clinically 
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meaningful change in radiographic progression has markedly diminished in the 
context of more modern treatment. 
Significance and Innovations 
• Radiographic damage at baseline and progression over the first 5-years has 
reduced over the last 25-years. 
• Joint space narrowing is the main driver for reductions in radiographic 
progression early after diagnosis, with reductions in erosions contributing 
later in the disease course. 
• RF+ RA remains a significant predictor of increased radiographic damage, 
however in the context of overall reductions, it is no longer associated with 
clinically-meaningful changes in radiographic damage. 
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Published literature has suggested that the incidence of Rheumatoid Arthritis (RA) 
has declined over the last three decades
1–9
. This corresponds with reports of declines 
in disease activity
10,11
 , functional disability
12,13
, orthopaedic surgery
14
 and 
radiographic progression
12,15,16
.  
While the causes are not entirely clear, it is hypothesised that these declines in 
disease severity are related to widespread changes in treatment strategies during 
the 1990s
17
. Data from randomised controlled trials (RCTs) have demonstrated that 
early initiation of conventional synthetic Disease Modifying Anti-Rheumatic Drugs 
(DMARDs) can significantly improve patient outcomes, particularly the increased use 
of methotrexate in combination with other DMARDs
18–21
, and indeed biologic 
DMARDs
22–25
. 
Radiographic joint damage is often used in RCTs as a primary outcome, and has been 
shown to be strongly related to levels of functional disability
26
 and disease activity
27
. 
Although commonly expressed as a global score
28
, radiographic joint damage 
comprises two main components, erosions and joint space narrowing (JSN). While 
related, they are thought to be the result of two distinct pathophysiological 
mechanisms
29,30
. Possible causes of erosive joint destruction are the products of 
invading synovium into the boney structures of the joints, and increased osteoclast 
activity
31
. In contrast, JSN has been hypothesised to reflect cartilage damage as a 
result of metalloproteinases, which are upregulated by pro-inflammatory 
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cytokines
32
. JSN is common to a range of pathologies, including osteoarthritis (OA), 
which is a common comorbid condition in people with RA
33
. Despite this, much of 
the focus of longitudinal data concerning radiographic damage has reported the 
combination of these two processes as one composite score
29,30
, for example using 
the radiographic scoring methods of Ratingen or Larsen, that lack the ability to 
distinguish progression of erosions and JSN as separate domains
12,15,16
.  
Further still, rheumatoid factor (RF) status has been strongly associated with worse 
radiographic progression
34–36
, however, to date no study has looked at whether the 
relative strength of this association has changed given the wider demographic 
changes seen in many other aspects of RA, including disease severity. It might be 
hypothesised that radiographic measures of RA will show significant changes given 
declines in disease activity, but whether previously demonstrated risk factors for 
progression continue to be influential remains unclear. 
This study therefore aims to investigate long-term radiographic progression by 
comparing data from two UK, multi-centre inception cohorts, the Early RA Study 
(ERAS), which collected patient data from 1986-2001, and the Early RA Network 
(ERAN), which collected data from 2002-2013. Specifically, this study 1) compares 
the total SvdH, erosion and JSN scores at baseline and the rate of progression over 
the first 5-years between the two cohorts, and 2) estimates the association between 
RF status and radiographic damage at baseline and progression over the first 5-years 
in ERAS and ERAN. 
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Patients and Methods 
The data used for this study were collected from two longitudinal inception cohorts, 
ERAS and ERAN. ERAS recruited 1,465 patients from 9 centres across the UK 
between 1986-2001, while ERAN recruited 1,236 patients from 25 centres between 
2002 and 2013. Two centres recruited to both cohorts. All patients had a confirmed 
diagnosis of RA and were recruited within 3 years of symptom onset, typically prior 
to conventional DMARD initiation. Maximum follow-up for ERAS was 25 years 
(median 10 years) and for ERAN was 11 years (median 3 years). All patients were 
treated based on standard clinical practice of the time. 
Standard clinical, laboratory and radiographic data were collected at baseline, 3 to 6 
months, 12 months, and then yearly thereafter. These included the original three 
variable 44-joint Disease Activity Score (DAS) for ERAS and the DAS28 for ERAN, the 
Health Assessment Questionnaire (HAQ), Rheumatoid Factor Positivity and 
haemoglobin level. To enable comparison of disease activity across the two cohorts, 
the original DAS in ERAS was converted to DAS28 using the formula DAS28 = 
(1.072*DAS) + 0.938
37
. 
Radiographic scoring 
Structural joint damage was assessed from plain radiographs using the SvdH scoring 
method
38
. All 32 centres collected yearly plain x-rays of hands and feet. Radiographs 
from all 9 centres recruiting from ERAS, and 7/25 (28%) centres from ERAN scored 
films using the SvdH method. 
The SvdH rates radiographic damage based on the prevalence and severity of the 
erosions in 32 joints in the hands and 12 joints in the feet, and the prevalence and 
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severity of JSN in 30 joints in the hands and 12 joints in the feet. Each joint was rated 
from 0-5 (or 0-10 for erosions in the joints of the feet) giving a maximum score of 
280 for the erosion score and 168 for the JSN score. These scores were combined to 
give a total SvdH score ranging from 0 to 448. 
One person (KJ) scored the radiographs for ERAS, while another person (DMcW) 
scored the radiographs for ERAN. Each scorer rated the radiographs in chronological 
order. To assess agreement between the two, both scored a random sub-sample 
of thirty-nine radiographs from twenty patients from the ERAS cohort at two time-
points (baseline and 5 years). An Intra-class Correlation Coefficient (ICC) of 
0.95 (95% confidence intervals 0.90-0.97) was calculated for the erosion score, and 
0.98 (95% CI 0.95-0.99) calculated for both the JSN score and total SvdH score. The 
ICC is an estimate of the proportion of the total variability in ratings for the sample 
that are due to variability between x-rays, rather variability within x-rays between 
readers. The high values in our assessment of agreement confirm the risk 
of systematic bias due to two readers is low, and as such the level of agreement 
acceptable for the comparison of trends over time. 
Statistical analysis 
To assess differences in the use of first-line conventional DMARDs between the two 
cohorts, the cumulative incidence of time to first DMARD within the first 12 months 
from first outpatient appointment was estimated. This was estimated for any 
DMARD use, as well as separate estimates for the two most commonly used first-line 
DMARDS, methotrexate and sulphazalasine. 
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The skewed distributions of radiographic scores derived by the SvdH method renders 
linear regression inappropriate
39
. Generalised linear regression with a negative-
binomial distribution, henceforth negative binomial regression (NBR), was found to 
achieve best fit to the data, compared with linear and Poisson distributions.  
Mixed-effects NBR (MENBR) models allowed for the longitudinal structure of the 
data to be modelled appropriately, whereby random intercept and time slope 
parameters were estimated. Cohort membership (either ERAS or ERAN) was the 
main covariate of interest. Baseline scores, along with yearly measures of SvdH were 
used in the models to estimate rates at presentation and over the 5-year follow-up. 
Missing data is inherent in longitudinal studies. To probe potential selection bias 
based on the availability of radiographs, baseline characteristics of those with and 
without radiographic data were compared. Furthermore, protecting against 
confounding due to missing longitudinal data, mixed-effects models use full 
information maximum likelihood making use of all available data under the missing 
at random assumption, so that all patients with data are included. 
Time was defined as years from enrolment and was included as a continuous 
variable with a random slope to allow for the estimation of the annual rate of 
progression for each patient. RF status was the secondary covariate of interest and 
entered as a main effect, along with a three-way interaction term with cohort and 
time to allow for progression rates to be estimated separately by RF status for each 
cohort. Sensitivity analysis, which substituted cohort membership for year of 
diagnosis in the model, was used to investigate the effect of calendar year on long-
term radiographic progression. Sex, age, DAS28, HAQ, low Hb (<12 for females /<13 
for males), months from symptom onset to first rheumatology visit, steroid use prior 
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to first assessment and DMARD use within first 12-months were all entered into the 
model to control for any potential confounding effects. 
Exponentiated regression coefficients of an NBR model are incidence rate ratios 
(IRR), which are interpreted as the relative increase in the log-count of the 
dependent variable (i.e. the SvdH score) given a one-unit increase in the respective 
covariate (e.g. age). To aid interpretation, the results from the models were also 
expressed as an absolute change in the SvdH score using the estimated mean SvdH, 
along with 95% Confidence Intervals [95% CI]. This allowed for a more direct 
interpretation of the effect that each factor had in terms of absolute difference in 
SvdH units, the percentage of maximum possible damage, and annual progression 
greater than the minimum clinically important difference of 5 units
40
.  
These models were estimated separately for the total SvdH score, JSN and erosion 
score. All analyses were conducted using Stata (version 14; StataCorp LP, USA). 
Results 
Of the 2,701 total patients recruited, 1,662 had SvdH data: 1,216 from ERAS and 446 
from ERAN. The demographic and baseline clinical characteristics of both ERAS and 
ERAN patients, including only those with radiographic data, are shown in Table 1. 
Reasons for missing radiographic data included loss of records, unreadable 
radiographs and loss to follow-up. Patients from ERAS were marginally younger at 
presentation and had higher DAS28, ESR, HAQ and were more likely to be anaemic at 
baseline, but the median time from first symptom to first visit was the same. Patient 
characteristics with recorded radiographic data were similar to the total patients in 
their respective cohort. 
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Table 1 - Summary Statistics for each Cohort 
 
Differences in treatment strategies between the two Cohorts 
For all DMARDs, ERAS reported a 12-month cumulative incidence of 71.6% [95%CI 
69.2-73.8] and for ERAN 95.3% [95%CI 93.9-96.4] (See Figure 1). The 12-month 
cumulative incidence of sulfasalazine (SSZ) use was higher in ERAS (55% [95%CI 52.4-
57.5]) than ERAN (33.1% [95%CI 30.4-35.8]), while methotrexate (MTX) use was 
substantially lower in ERAS (1.4% [95%CI 0.9-2.1]) compared to ERAN (52.1% [95%CI 
49.2-55.0]). 
Figure 1. 12-month Cumulative Incidence of DMARD use for ERAS and ERAN 
 
Radiographic progression rates of ERAS and ERAN 
For the MENBR analysis a total of 1,508 patients contributing 5,430 observations 
(mean observations per patient = 3.6) were included. Overall, the ERAN cohort 
exhibited a 41% lower total SvdH score at baseline compared to ERAS (IRR 0.59 
[95%CI 0.50-0.70], p<0.001), along with a 65% slower annual rate of progression 
over the first 5-years (IRR 0.35 [95%CI 0.24-0.47], p<0.001) (See Figure 2A). The 
differences in absolute and relative scores for both cohorts are shown in Table 2. 
When expressed as a proportion of maximum possible damage, the estimated values 
indicated an increase of 1.5% [95%CI 1.4-1.7] per year for ERAS and 0.6% [95%CI 0.4-
0.7] per year for ERAN. The total proportion of patients who had annual progression 
estimated to be greater than the MCID (≥5 SvdH units) was 74% for ERAS and 27% 
for ERAN. Sensitivity analysis modelling calendar year, rather than cohort, indicated 
that each additional calendar year decreased the risk of radiographic progression by 
3% (IRR 0.97 [95%CI 0.96-0.99], p<0.05). Additional sensitivity analysis also 
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controlling for baseline BMI found that while increased BMI at baseline was 
protective of increased radiographic damage over the first 5 years, it did not alter 
the main cohort effect (results not shown). 
 
Table 2. Mean and relative difference in baseline level and annual rate of 
progression for Total SvdH, JSN and erosion scores between 1986-2001 (ERAS) and 
2002-2013 (ERAN). Estimates based on fixing the values of the covariates to the 
sample means. Controlling covariates = age, sex, RF status, baseline DAS28, 
baseline HAQ, low Hb (<12/13) at baseline, months from symptom onset to first 
rheumatology visit, steroid use prior to first assessment and DMARD use 
 
Similar results were seen for the JSN score, with ERAN participants displaying lower 
scores at baseline (IRR 0.49 [95%CI 0.41-0.58], p<0.001) and a slower annual rate of 
progression over the first 5-years compared to ERAS (IRR 0.31 [95%CI 0.21-0.42], 
p<0.001) (See Figure 2B).  
For the erosion score, the score at baseline was similar for both cohorts (IRR 0.94 
[95%CI 0.73-1.19], p=0.593), however, ERAN exhibited a slower annual rate of 
progression over the first 5-years compared to ERAS (IRR 0.43 [95%CI 0.25-0.61], 
p<0.001) (See Figure 2C). See Table 2 for absolute and relative changes in both JSN 
and erosion scores between the two cohorts. 
Figure 2 - Progression of A) Total SvdH, B) JSN and C) Erosion score for 1986-2001 
(ERAS) and 2002-2013 (ERAN) 
 
Association of RF status with radiographic progression in ERAS and ERAN 
The absolute and relative difference in total SvdH scores for RF+ and RF- patients in 
both cohorts are given in Table 3 and displayed graphically in Figure 3. For the total 
SvdH score, RF+ RA was not significantly associated with increased radiographic 
damage at baseline, compared to RF- RA, in either ERAS or ERAN. RF+ RA was 
associated with a 70% increased annual rate of progression, compared to RF- RA, in 
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ERAS, which was statistically significant. The annual rate of progression for RF+ RA, 
compared to RF- RA, in ERAN was increased by 9%, which was not significant. This 
relates to decreases in the relative impact of RF+ RA on the annual rate of 
progression of 36% for ERAN compared to ERAS, which although considerable was 
non-significant (IRR 0.64 [95%CI 0.29-1.07], p=0.224). This related to the proportion 
of RF+ patients with an annual progression greater than the MCID of 80% for ERAS 
and just 29% for ERAN.  
Investigation of the association between RF+ RA in both the cohorts for the separate 
JSN and erosion score indicated similar results to the total SvdH (See Supplementary 
Material 1). 
Figure 3 - Progression of Total SvdH score for ERAS and ERAN stratified by RF status  
 
 
Table 3. Mean and relative difference in baseline level and annual rate of 
progression for Total SvdH based on RF status between 1986-2001 (ERAS) and 
2002-2013 (ERAN). Estimates based on fixing the values of the covariates to the 
sample means. Controlling covariates = age, sex, baseline DAS28, baseline HAQ, 
low Hb (<12/13) at baseline, months from symptom onset to first rheumatology 
visit, steroid use prior to first assessment and DMARD use 
 
Discussion 
The findings from the present study indicate that patients with early RA with onset 
from 2002-2013 (ERAN) had significantly lower baseline and annual rates of 
radiographic progression compared to those with onset from 1986-2001 (ERAS). 
Examination of the separate erosion and JSN scores indicate that the reduction in 
the total SvdH score was largely driven by less JSN. Strikingly, the strong association 
of RF status and increased radiographic progression in the earlier time period (ERAS) 
was markedly diminished in the later time period (ERAN). Those with RF+ RA from 
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2002-2013 had markedly better radiographic outcomes at 5 years than those with 
RF- RA in 1986-2001.  
Previous research has indicated that a change of 5 SvdH units indicates a minimal 
clinically important difference
40,41
, therefore a difference of 5 units per year for 
ERAN compared to ERAS on total SvdH score observed in this study demonstrates 
not only a statistically significant change in progression, but also a clinically 
meaningful reduction. Whereas 74% of patients in the earlier cohort progressed on 
average ≥5 units per year over the 5-year period of follow-up considered, just 27% of 
patients in the later cohort did.  
Our data extend previous findings of reductions in radiographic damage in RA over 
recent decades 
12,15,16
. There are two plausible explanations for these findings, both 
of which are likely to contribute to the reduction in radiographic damage over time. 
Firstly, RA may have become milder, and secondly, earlier more intensive treatment 
may have improved disease outcomes. Our models adjusted for disease severity at 
baseline, but it remains possible that lower rates of progression in the more recent 
cohort reflect milder disease. This is supported by the observation of lower SvdH 
scores in ERAN compared to ERAS at baseline, prior to DMARD initiation, even 
though the median time from first symptom to first visit was the same for both 
cohorts. However, the reduction in radiographic progression is likely to also reflect 
improvements in the treatment of RA, given the earlier and increased use of 
methotrexate as the first line DMARD observed in ERAN in this study, which is in line 
with other reports 
12,15,16,36
. Increasing evidence from RCTs also support the 
hypothesis that early, intensive treatment has an important effect on reducing 
radiographic progression
42–46
. 
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Separate investigation of the erosion and JSN components of radiographic damage 
scores showed that JSN was the primary driver for the overall reductions seen in the 
total SvdH score between the two cohorts. This finding reiterates the importance of 
reporting both the erosion and JSN score separately in clinical trials. Data from 
ASPIRE show that more patients with early RA have either erosions alone (8.5%) or 
JSN alone (4.4%), than both (3.7%) at baseline visit
30
, and that JSN may be more 
strongly associated with irreversible disability
29
. Despite this, the separate scores are 
still rarely reported
28
. If early treatment with MTX was the primary cause for the 
reduction in total SvdH in ERAN, this could indicate that the mechanism by which 
this is achieved is through the reduction of JSN and preservation of the surrounding 
cartilage. However, what is not clear is whether the JSN is directly attributable to RA 
JSN, or OA JSN. A high prevalence of radiographic OA has been documented at 
baseline in the ERAN cohort in the hands and feet, indicating that high levels of 
comorbid OA could potentially confound any radiographic assessment of RA
33
. High 
JSN scores are strongly associated with increased severity of OA osteophytosis and 
OA JSN
47
. More studies are needed to quantify the exact effect that co-morbid OA 
could be having on RA radiographic scoring. 
Seropositive RA has been consistently associated with increased radiographic 
damage
35,36
. This study also found that RF+ RA was highly associated with increased 
radiographic progression. However, when investigating the absolute change in 
radiographic score between RF+ and RF- patients across the two cohorts, RF+ 
patients between 2002-2013 no longer represented a patient sub-group with 
clinically meaningful increases in radiographic progression, at least within the first 5-
years of disease. Aletaha et al.
48
 analysed the effect of seropositive status on 
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radiographic progression and found seropositive patients displayed higher 
radiographic progression, compared to seronegative patients
39,49
. The estimated 
change in median SvdH score of 0.6 units per year for seropositive over that of 
seronegative patients provides an estimate similar to this study.  
Many RCTs are restricted to seropositive patients only, and previous research has 
not focused on the effect of seropositivity in the context of reduced radiographic 
progression in more recent years. The two long-term observational cohorts 
examined in this study provide a ‘real-world’ account of patients typically seen in 
secondary care, and the high patient numbers over the full 5-year follow-up also 
provides a unique opportunity to provide precise estimates using the modelling 
techniques outlined
39
. The use of the SvdH score also provides a first look at the two 
principle components of radiographic damage, erosions and JSN, in detail. Further 
data from observational studies are needed to ascertain whether reductions in 
radiographic progression have also resulted in the diminished association with RF 
status, particularly in the context of anti-CCP seropositive RA, which could be more 
predictive of radiographic progression when compared to RF
36,50,51
. 
Our research is subject to a number of limitations inherent in cohort studies. 
Recruiting centres were hosted by enthusiastic clinicians within the UK and, although 
they might not necessarily reflect people with RA in other contents, or subjected to 
different treatment regimens, the multicentre recruitment for these cohorts from 
district general hospitals is likely to be representative of people with RA in the UK. 
Radiographs were not available for all participants, and it is possible that those with 
more severe disease were more likely to have x-rays, increasing the risk of selection 
bias in our study. However, baseline variables indicated minimal differences 
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between the whole cohorts, and those for whom radiographic data were available. 
The impact of such a selection bias would overestimate rates of progression, 
particularly for ERAN, where data were less complete; hence our estimates should 
be treated as conservative. 
This study provides further evidence into the marked reduction in radiographic 
damage over the last 25-years, while providing accurate, quantified estimates of the 
extent of that reduction. JSN was the major driver for the overall reductions seen, 
and highlights the importance of investigating JSN and erosions separately when 
investigating radiographic damage. Advances in treatment are likely to be the main 
cause for the decline, and adequate DMARD treatment might remove the predictive 
value of RF status for radiographic progression in early RA. Further research should 
seek other predictors and mediators if residual radiographic progression despite 
DMARD treatment is to be halted. The impact of these reductions on patients of 
varying disease severity, and whether these reductions have an impact on improved 
long-term functional disability will be crucial in fully realising the impact of these 
results on clinical care. 
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Tables and Figures 
 
Table 1 - Summary Statistics for each Cohort 
 
     ERAS Total    ERAN Total     ERAS+ERAN 
Total 
n=1465 
With SvdH 
n=1216 
Missing 
n(%) 
Total 
n=1236 
With SvdH 
n=446 
Missing 
n(%) 
Total 
n=2701 
With SvdH 
n=1662 
Demographics   
Year of Recruitment 1986-2001 1986-2001 0 (0) 2002-2013 2002-2013 0 (0) 1986-2013 1986-2013 
Age at Onset (Mean (SD)) 55.3 (14.6) 54.9 (14.5) 0 (0) 57.1 (14) 58 (13.5) 0 (0) 56.1 (14.4) 55.7 (14.3) 
Female (%) 66 66 0 (0) 68 65 0 (0) 67 65 
Clinical Markers   
Rheumatoid Factor + (%) 63 64 9 (0.1) 60 61 142 (11) 62 63 
Baseline DAS (Mean (SD)) 6.32 (1.33) 6.32 (1.33) 13 (0.1) 4.53 (1.58) 4.5 (1.64) 46 (4) 5.51 (1.7) 5.84 (1.62) 
Baseline ESR (Median (IQR)) 37 (44) 38 (44) 7 (0.1) 24 (29) 21 (28) 183 (15) 30 (39) 34 (41) 
Baseline HAQ (Mean (SD)) 1.15 (0.8) 1.15 (0.8) 5 (0.1) 1.08 (0.8) 1.03 (0.8) 37 (3) 1.12 (0.8) 1.12 (0.8) 
Baseline Anaemia (%) 41 42 5 (0.1) 28 24 32 (3) 35 37 
Months from symptom 
onset to First Visit (Median 
(IQR)) 
6 (7) 6.5 (7) 0 (0) 6 (8) 6 (8) 91 (7) 6 (8) 6 (8) 
Treatment         
DMARD use (12 months (%)) 73 73 38(3) 96 98 276(22) 82 79 
    Methotrexate 2 2  57 64  24 17 
    Sulphazalzine 55 55  31 28  46 49 
   Hydrochloroquine 14 13  3 3  9 11 
   Other 2 2  4 2  3 2 
Numbers represent means (SD), medians (IQR) and proportions were used where indicated. 
SvdH = Sharp/van der Heijde, DAS=Disease Activity Score-28, ESR=Erythrocyte Sedimentation Rate, HAQ = Health Assessment Questionnaire. 
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Table 2. Mean and relative difference in baseline level and annual rate of 
progression for Total SvdH, JSN and erosion scores between 1986-2001 (ERAS) and 
2002-2013 (ERAN). Estimates based on fixing the values of the covariates to the 
sample means. Controlling covariates = age, sex, RF status, baseline DAS28, baseline 
HAQ, low Hb (<12/13) at baseline, months from symptom onset to first 
rheumatology visit, steroid use prior to first assessment and DMARD use 
 
Estimated 
means 
ERAS ERAN 
Absolute 
Difference 
Relative 
Difference (IRR) 
[95% CI] 
 
P-Value 
Total SvdH at 
baseline 
10.5 6.2 4.3  0.59 [0.50-0.70]  <0.001 
Total SvdH 
annual rate 
6.9 2.5 4.5  0.35 [0.24-0.47]  <0.001 
JSN score at 
baseline 
7.4 3.6 3.8  0.49 [0.41-0.58]  <0.001 
JSN score 
annual rate 
3.9 1.2 2.7  0.31 [0.21-0.42]  <0.001 
Erosion score 
at baseline 
1.8 1.7 0.1  0.94 [0.73-1.19]  0.593 
Erosion score 
annual rate 
1.9 0.8 1.1  0.43 [0.25-0.61]  <0.001 
 
 
Table 3. Mean and relative difference in baseline level and annual rate of 
progression for Total SvdH based on seropostive (RF+) status between 1986-2001 
(ERAS) and 2002-2013 (ERAN). Estimates based on fixing the values of the covariates 
to the sample means. Controlling covariates = age, sex, baseline DAS28, baseline 
HAQ, low Hb (<12/13) at baseline, months from symptom onset to first 
rheumatology visit, steroid use prior to first assessment and DMARD use 
 
 
  RF- RF+ Difference 
Relative 
Difference (IRR) 
[95% CI] 
P-Value 
ERAS 
Total SvdH 
at baseline 
9.5 11 1.5 1.16 [1.00-1.35] 0.056 
Total SvdH 
Annual rate 
5.1 8.6 3.6 1.70 [1.42-1.97] <0.001 
ERAN 
Total SvdH 
at baseline 
6.0 6.2 0.2 1.04 [0.76-1.42] 0.811 
Total SvdH 
Annual rate 
1.9 2.0 0.2 1.09 [0.51-1.67] 0.855 
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Figure 1. 12-month Cumulative Incidence of DMARD use for 1986-2001 (ERAS) and 
2002-2013 (ERAN) 
 
 
Figure 2 - Progression of A) Total SvdH, B) JSN and C) Erosion score for 1986-2001 
(ERAS) and 2002-2013 (ERAN) 
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Figure 3 - Progression of Total SvdH score for 1986-2001 (ERAS) and 2002-2013 
(ERAN) stratified by RF status  
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STROBE Statement—Checklist of items that should be included in reports of cohort studies  
 Item 
No Recommendation 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 
[Included in Title on page 1] 
(b) Provide in the abstract an informative and balanced summary of what was done 
and what was found [See objectives and conclusion in abstract on page 2] 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
[Page 3 & 4] 
Objectives 3 State specific objectives, including any prespecified hypotheses [Page 2] 
Methods 
Study design 4 Present key elements of study design early in the paper [Page 4] 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection [Page 4 & 5] 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up [Page 4] 
(b) For matched studies, give matching criteria and number of exposed and 
unexposed [N/A] 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable [Page 4 & 5] 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if there is 
more than one group [Page 5] 
Bias 9 Describe any efforts to address potential sources of bias [Page 6] 
Study size 10 Explain how the study size was arrived at [Page 4] 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why [Page 5 & 6] 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 
[Page 5 & 6] 
(b) Describe any methods used to examine subgroups and interactions [Page 6] 
(c) Explain how missing data were addressed [Page 6] 
(d) If applicable, explain how loss to follow-up was addressed [Page 6] 
(e) Describe any sensitivity analyses [N\A] 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed [Page 7] 
(b) Give reasons for non-participation at each stage [Page 7] 
(c) Consider use of a flow diagram [N/A] 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders [Page 7] 
(b) Indicate number of participants with missing data for each variable of interest 
[Page 7] 
(c) Summarise follow-up time (eg, average and total amount) [Page 8] 
Outcome data 15* Report numbers of outcome events or summary measures over time [Page 8] 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (eg, 95% confidence interval). Make clear which confounders were 
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adjusted for and why they were included [Page 8 & 9 & 10] 
(b) Report category boundaries when continuous variables were categorized [N/A] 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period [Page 8 & 9 & 10] 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and 
sensitivity analyses [N/A] 
Discussion 
Key results 18 Summarise key results with reference to study objectives [Page 9] 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias [Page 12 & 
13] 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
[Page 11 & 12] 
Generalisability 21 Discuss the generalisability (external validity) of the study results [Page 12] 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based [N/A] 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
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